Thomas B Karasic1, E Gabriela Chiorean2, Said M Sebti3, Peter J O'Dwyer4. 1. University of Pennsylvania, Philadelphia, Pennsylvania, USA. thomas.karasic@pennmedicine.upenn.edu. 2. University of Washington, Seattle, Washington, USA. 3. H. Lee Moffitt Cancer Care and Research Center, Tampa, FL, USA. 4. University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract
BACKGROUND: Geranylgeranyltransferase I (GGTase I) catalyzes geranylgeranylation, a modification required for the function of many oncogenic RAS-related proteins. GGTI-2418 is a peptidomimetic small molecule inhibitor of GGTase I. OBJECTIVE: The aim of this study was to establish the maximum tolerated dose of GGTI-2418 in patients with advanced solid tumors. PATIENTS AND METHODS: This was a phase I, open-label, dose-escalation study conducted in two US centers (University of Pennsylvania and Indiana University) in adults with treatment-refractory advanced solid tumors. An accelerated dose-escalation schema was used across eight dose levels, from 120 to 2060 mg/m2, administered on days 1-5 of each 21-day cycle. RESULTS: Fourteen patients were enrolled in the dose-escalation cohort. No dose-limiting toxicities were observed, and 2060 mg/m2 was determined to be the maximum tolerated dose. The only potential drug-related grade 3 or 4 toxicities were elevated bilirubin and alkaline phosphatase in a single patient with concurrent malignant biliary obstruction. No objective responses were observed. Four of thirteen evaluable patients had stable disease for up to 6.7 months. The study was terminated prior to dose expansion based on a sponsor decision. Pharmacokinetic analysis demonstrated a mean terminal half-life of 1.1 h. CONCLUSIONS: GGTI2418 was safe and tolerable at all tested dose levels with some evidence of disease stability. Due to rapid elimination, dosing of GGTI2418 in this study may have been inadequate to achieve optimal inhibition of its target, GGTase I.
BACKGROUND: Geranylgeranyltransferase I (GGTase I) catalyzes geranylgeranylation, a modification required for the function of many oncogenic RAS-related proteins. GGTI-2418 is a peptidomimetic small molecule inhibitor of GGTase I. OBJECTIVE: The aim of this study was to establish the maximum tolerated dose of GGTI-2418 in patients with advanced solid tumors. PATIENTS AND METHODS: This was a phase I, open-label, dose-escalation study conducted in two US centers (University of Pennsylvania and Indiana University) in adults with treatment-refractory advanced solid tumors. An accelerated dose-escalation schema was used across eight dose levels, from 120 to 2060 mg/m2, administered on days 1-5 of each 21-day cycle. RESULTS: Fourteen patients were enrolled in the dose-escalation cohort. No dose-limiting toxicities were observed, and 2060 mg/m2 was determined to be the maximum tolerated dose. The only potential drug-related grade 3 or 4 toxicities were elevated bilirubin and alkaline phosphatase in a single patient with concurrent malignant biliary obstruction. No objective responses were observed. Four of thirteen evaluable patients had stable disease for up to 6.7 months. The study was terminated prior to dose expansion based on a sponsor decision. Pharmacokinetic analysis demonstrated a mean terminal half-life of 1.1 h. CONCLUSIONS:GGTI2418 was safe and tolerable at all tested dose levels with some evidence of disease stability. Due to rapid elimination, dosing of GGTI2418 in this study may have been inadequate to achieve optimal inhibition of its target, GGTase I.
Authors: Hairuo Peng; Dora Carrico; Van Thai; Michelle Blaskovich; Cynthia Bucher; Erin E Pusateri; Said M Sebti; Andrew D Hamilton Journal: Org Biomol Chem Date: 2006-03-21 Impact factor: 3.876
Authors: John M Lambert; Que T Lambert; Gary W Reuther; Angeliki Malliri; David P Siderovski; John Sondek; John G Collard; Channing J Der Journal: Nat Cell Biol Date: 2002-08 Impact factor: 28.824
Authors: Kian-Huat Lim; Antonio T Baines; James J Fiordalisi; Michail Shipitsin; Larry A Feig; Adrienne D Cox; Channing J Der; Christopher M Counter Journal: Cancer Cell Date: 2005-06 Impact factor: 31.743
Authors: Anna-Karin M Sjogren; Karin M E Andersson; Meng Liu; Briony A Cutts; Christin Karlsson; Annika M Wahlstrom; Martin Dalin; Carolyn Weinbaum; Patrick J Casey; Andrej Tarkowski; Birgitta Swolin; Stephen G Young; Martin O Bergo Journal: J Clin Invest Date: 2007-05 Impact factor: 14.808
Authors: Nesrin M Hamad; Joel H Elconin; Antoine E Karnoub; Wenli Bai; Jeremy N Rich; Robert T Abraham; Channing J Der; Christopher M Counter Journal: Genes Dev Date: 2002-08-15 Impact factor: 11.361
Authors: Staci L Haney; Michelle L Varney; Yashpal Chhonker; Geoffrey Talmon; Lynette M Smith; Daryl J Murry; Sarah A Holstein Journal: Pharmacol Res Date: 2021-03-03 Impact factor: 7.658